Modular Payloads for Unmanned aircraft systems (UAS) : This contract opportunity seeks to revolutionize UAS capabilities through modular payloads compatible with the Picatinny Common Lethality Interface Kit
As for cons: Repeated injections in the same area can cause lipohypertrophy , a condition in which the fat under the skin thickens or hardens

Key Takeaways No commercial retatrutide pen exists: Eli Lilly has not FDA-approved or publicly released any branded retatrutide auto-injector as of May 2026 Phase 3 TRIUMPH trials confirm subcutaneous injection once weekly, but the specific device format has not been disclosed by Lilly Grey-market pens are not Lilly products: The "SALKALLI" DailyMed entry is a Chinese export-only product (Guangzhou Yixin Co.), not FDA-approved for US use Phase 3 TRIUMPH-4 results showed 28.7% weight loss at 68 weeks on 12mg, the strongest obesity trial result on record When approved (2027 earliest), a once-weekly auto-injector similar to Lilly's KwikPen format is widely anticipated Use the retatrutide pharmacokinetic calculator to plan dosing regardless of delivery format 28.7% Phase 3 TRIUMPH-4 Weight Loss ~6 days Half-Life (Once-Weekly Dosing) 12mg Maximum Dose (Phase 3) 2027 Earliest Likely US Launch Does Retatrutide Come in a Pen

For patients with diabetes, caution is advised regarding potential worsening of diabetic retinopathy, particularly with rapid improvements in glycaemic control
While tirzepatides use for weight loss may be considered off-label unless specifically approved by the FDA (such as under the brand name Zepbound), it is becoming an increasingly popular option for medically supervised weight management
Your CosmeSurge specialist will track your progress and adjust your plan accordingly